Blog

Advancing Oncology Drug Development with Precision Medicine

Traditionally a disease has been defined by its clinical presentation and observable characteristics, not by the underlying molecular mechanisms, pathways and biological processes specific to a particular patient.

This can lead to classifying what are often highly heterogeneous medical conditions as a single disease.

In recent years, the healthcare industry has made significant steps in further understanding and targeting the underlying molecular cause of disease, however there is much more to be done. Consequently, patients with the same disease diagnosis tend to receive the same treatment. This kind of one-size-fits-all treatment strategy inadequately accounts for inter-individual variability between patients or the stage of their disease course. The result is that a large number of patients fail to respond to the treatments they are prescribed for.

One obvious example is cancer, which is a heterogeneous disease, with both between-patient variability and differences in the characteristics of disease within a given patient, making developing long-term cures challenging in many cancer types. Over the past decades, there have been major advances in developing cancer therapeutics; patients who receive targeted therapies have benefitted from improved survival [1,2,3]. However, there is still a huge unmet need for patients who either do not respond to existing treatments or develop resistance to them.

Our Precision Medicine team is working to change this by starting drug discovery from endotypes - groups of patients with the same underlying cause of disease.  By stratifying patients, we believe we have a better chance at identifying responder patients, designing more effective clinical trials and developing new therapies for complex and heterogeneous diseases like cancer.

Our team takes a multi-disciplinary approach to leverage the vast collection of patient-level data produced by recent developments in technology. We apply machine learning, bioinformatics, biological knowledge, and translational medicine to advance our drug discovery programs with a data driven approach. We use unsupervised machine learning techniques to capture patient heterogeneity and uncover different underlying biological mechanisms within the disease. We then incorporate these new insights into our core biomedical knowledge graph for drug target identification.

Our approach has been used in multiple discovery programs in disease areas such as neurology and oncology. Recently we announced our collaboration with Novartis Global Drug Development, where we are investigating new indications and responders for Novartis oncology medicines currently in clinical development. With this initiative, we combine expertise from both parties to further expedite the process of delivering the next generation of cancer therapies to the clinic.  

Our focus on precision medicine is important because we are translating scientific discoveries into real-world practice more efficiently, to more precisely target medicines for the patients who need them most.


Pijika Watcharapichat, Senior Research Scientist, Health Informatics

More Posts

You Might Also Like

Events
BenevolentAI at ICML 2020
We are pleased to announce that BenevolentAI is sponsoring the virtual ICML 2020 conference from the 12th - 18th of July. You can find our team on the EXPO workshop and Women in ML stage - we hope to meet you there.
Jul 12, 2020
News
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
Jul 1, 2020
News
COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair
David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.
Jul 1, 2020
Events
New tech brings new hope in our new normal | A Keynote from Joanna Shields at WeAreTechWomen
In this talk, Joanna Shields will demonstrate how human intelligence partnered with technology promises to accelerate new discoveries, new treatments, and new hope for patients.
Jun 26, 2020
Events
Transforming Biopharmaceutical Research with AI at The HESI Annual Meeting 2020.
Our Executive board director, Jackie Hunter, will take to the virtual stage to demonstrate how AI can be used right at the beginning of the R&D process to improve target identification and validation as well as being used to identify key pathways in disease
Jun 9, 2020
Video
How do we get the next 10 years right? | CogX Opening Keynote w/ Joanna Shields
“We need leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all". Our CEO Joanna Shields opens CogX 2020 sharing inspiration for the next decade.
Jun 8, 2020